Catalyst Event

Samsung Biologics Co Ltd (207940) · Other

From Akros K-Manufacturing 50 Index (AKMNF50)

3/20/2026, 12:00:00 AM

OtherSentiment: Positive

Announced a KRW 520 billion capital increase for its wholly-owned U.S. subsidiary, Samsung Biologics America, Inc., on March 20, 2026. High importance is estimated due to the significant strategic expansion into the U.S. market.

Korean Translation

2026년 3월 20일, 100% 자회사인 삼성바이오로직스 아메리카에 5,200억 원 규모의 유상증자를 결정함. 대규모 해외 시설 투자에 따른 전략적 중요성으로 높은 중요도가 예상됨.

Related Recent Events

View Full Timeline